Gemstone Biotherapeutics, a biotech company developing novel, bioengineered products for scar-free skin regeneration, today announced that Dr. Emily English has been named Chief Executive Officer and Heather Keith has joined the company as Director of Sales and Marketing.

Dr. English joined Gemstone a year ago as Chief Operating Officer and her promotion to CEO was recently approved by the board of directors. As CEO, she will lead the company’s overall strategic direction, including fundraising, innovation and commercialization efforts.

Mr. David Oros, Chairman, Board of Directors for Gemstone Biotherapeutics stated, “Under Emily's leadership, Gemstone has gained significant momentum this year. She has effectively led the company toward commercializing Gemstone's technologies, securing grants, and growing the team. Emily strategically balances both short-term and long-term objectives. She has had a strong impact on the company, and we are confident about Gemstone's continuing success under her direction.”

Ms. Keith, a veteran of the medical device industry, will lead marketing and sales efforts as Gemstone grows toward commercialization of its skin regeneration products. Prior to joining the Gemstone team in July, Ms. Keith worked in business development at Battelle, an applied science and technology development company based in Columbus, Ohio. She also served as CEO and founder of Strohl Medical Technologies; as well as the Director of Sales and Marketing at both TEI Biosciences, Inc. and Soluble Systems, LLC.

“Heather’s industry experience will provide Gemstone with invaluable insight as we continue to develop our skin regeneration products for the dermatology market,” Dr. English said. “This is an important time in our company’s journey and we are very excited to welcome Heather to the team.”

Gemstone is currently moving toward FDA submission and clearance for its first skin regeneration product. At the same time, recent SBIR grants from the National Institutes of Health (NIH) and National Science Foundation (NSF), as well as a grant from the Maryland Stem Cell Research Fund (MSCRF), have provided the company with non-dilutive funding to perform further research and development for additional applications of their technologies.

“It’s an exciting time to be a part of Gemstone Biotherapeutics,” Dr. English added. “Gemstone has made substantial scientific and product development progress over the past year. I am excited to lead our outstanding team as we develop products that solve unmet skin regeneration needs and improve patient's lives.”

About Gemstone Biotherapeutics

Gemstone Biotherapeutics is a Baltimore-based, biotech company developing innovative, evidence-based products for scar-free skin regeneration. Gemstone’s products have been bioengineered to target the healing cascade that stimulates rapid skin regeneration to restore healthy, stretchy, scar-free skin. The Company’s platform technology has the potential to transform the dermatology market with high-impact, functional and aesthetic benefits for patients and cost savings for the health care industry. For additional information, please visit www.gemstonebio.com.